Evidence map›Paper›PMID 39587630›Full record

ArticleBreast cancer research : BCR2024

Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients.

Meron Yohannes, Zelalem Desalegn, Marcus Bauer, Kathrin Stückrath, Endale Anberbir, Yonas Bekuretsion, Mathewos Assefa, Tariku Wakuma, Yasin Worku, Pablo S C Santos and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Meron YohannesDepartment of Microbiology, Immunology & Parasitology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Zelalem DesalegnDepartment of Microbiology, Immunology & Parasitology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Marcus BauerGlobal and Planetary Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Kathrin StückrathUniversity Clinic and Polyclinic for Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Endale AnberbirDepartment of Surgery, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Yonas BekuretsionDepartment of Pathology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Mathewos AssefaDepartment of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Tariku WakumaAira Hospital, Aira, Ethiopia.
Yasin WorkuSchool of Medicine, Wollo University, Wollo, Ethiopia.
Pablo S C SantosGlobal and Planetary Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Lesley TaylorCity of Hope National Medical Center, Duarte, CA, USA.
Adamu AdissieGlobal and Planetary Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Claudia WickenhauserInstitute of Pathology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Chiara MassaMedical Faculty, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Martina VetterUniversity Clinic and Polyclinic for Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Eva Johanna KantelhardtGlobal and Planetary Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Barbara Seliger *Medical Faculty, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
Tamrat Abebe *Department of Microbiology, Immunology & Parasitology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia. tamrat.abebe@aau.edu.et.

Funding

Deutsche Gesellschaft für Internationale Zusammenarbeit ID 81256434Deutscher Akademischer Austauschdienst ID 57216764Else Kröner-Fresenius-Zentrum für Ernährungsmedizin 2018_HA31SPSusan G. Komen GTDR16378013
6 · The paper itself

Abstract

backgroundThe clinical management of breast cancer (BC) is mainly based on the assessment of receptor expression by tumour cells. However, there is still an unmet need for novel biomarkers important for prognosis and therapy. The tumour immune microenvironment (TIME) is thought to play a key role in prognosis and therapy selection, therefore this study aimed to describe the TIME in Ethiopian BC patients.

methodsRNA was isolated from formalin-fixed paraffin-embedded (FFPE) tissue from 82 women with BC. Expression of PAM50 and 54 immune genes was analysed using the Nanostring platform and differentially expressed genes (DEGs) were determined using ROSALIND

resultsFour discrete immune phenotypes (IP1-4) were identified through hierarchical clustering of immune gene expression data. These IPs were characterized by DEGs associated with both immune activation and inhibition as well as variations in the extent of immune infiltration. However, there were no significant differences regarding PIK3CA mutations between the IPs. A downregulation of immune suppressive and activating genes and the lowest number of infiltrating immune cells were found in IP2, which was associated with luminal tumours. In contrast, IP4 displayed an active TME chracterized by an upregulation of cytotoxic genes and the highest density of immune cell infiltrations, independent of the specific intrinsic subtype. IP1 and IP3 exhibited intermediate characteristics. The IPs had a prognostic relevance and patients with an active TME had improved overall survival compared to IPs with a significant downregulation of the majority of immune genes.

conclusionImmune gene expression profiling identified four distinct immune contextures of the TME with unique gene expression patterns and immune infiltration. The classification into distinct immune subgroups may provide important information regarding prognosis and the selection of patients undergoing conventional treatments or immunotherapies.

Indexed as

Biomarkers, TumorBreast NeoplasmsGene Expression ProfilingGene Expression Regulation, NeoplasticLymphocytes, Tumor-InfiltratingTumor MicroenvironmentAdultAgedClass I Phosphatidylinositol 3-KinasesEthiopiaFemaleHumansMiddle AgedMutationPrognosisBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesPIK3CA protein, humanBreast cancerEthiopiaImmune phenotypesPAM50Tumour immune microenvironment

Identifiers

PMID39587630
PMCPMC11587711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.